The median age was 54 ± 15 years (range, 27–91 years), and the median sclerostin patients were divided into two groups according to sclerostin level using a receiver operating characteristic curve to determine the best-associated criterion value of sclerostin with pulmonary hypertension (Supplementary Fig. 1). The gene discussed is SOST; the disease is pulmonary hypertension.